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Abstract
This review summarizes the evidence that collagen IV binding is physiologically important, and that the
extravascular compartment of FIX is composed of type IV collagen. As we have previously demonstrated, 7 days
post-infusion, FIXWT (BeneFIX) is able to control bleeding as well as the same dosage of Alprolix in hemophilia B
mice, tested using the saphenous vein bleeding model (Alprolix is a chimeric FIX molecule joined at its C terminus
to a Fc domain). Furthermore, we have shown that in hemophilia B mice, doses of BeneFIX or Alprolix (up to a
dose of 150 IU/kg) have increased bleeding-control effectiveness in proportion to the dose up to a certain limit:
higher doses are no more effective than the 150 IU/kg dose. These studies suggest that in hemophilia B mice,
tested using the saphenous vein bleeding model, three things are true: first, extravascular FIX is at least as
important for coagulation as is circulating FIX; second, measuring circulating levels of FIX may not be the best
criterion for designing new “longer lasting” FIX molecules; and third, trough levels are less diagnostic for FIX
therapy than they are for FVIII therapy.
Keywords: FIX, Collagen IV, Coagulation, Hemophilia B
Abbreviations: FIX, Coagulation FIX; Hemophilia B, an individual or animal lacking FIX
Background
Hemophilia B is caused by the absence or defect of an
enzyme, coagulation factor IX (FIX). A plasma concen-
tration of ~5 μg per ml of FIX, defined to be one inter-
national unit (IU), is the approximate average plasma
concentration of pooled samples from normal
individuals.
Familial bleeding, or hemophilia, has been known
since biblical times. In 1952, several groups realized that
the blood of some hemophilia patients could correct co-
agulation in blood from other hemophilia patients [1–3].
This observation led to the designation of two types of
hemophilia: hemophilia A (FVIII deficiency) and
hemophilia B (FIX deficiency), which are clinically indis-
tinguishable. The designation of disease severity has
been well defined for hemophilia A. Generally, patients
who have less than 1 % of the normal circulating levels
of FVIII in their plasma are designated as severe cases
and have frequent occurrences of spontaneous bleeding.
Patients with between 1 and 5 % activity are designated
moderate cases; these patients experience bleeding pri-
marily after injury. Patients with levels between 5 and
50 % activity are considered to have mild hemophilia
and usually experience bleeds only with surgery or major
trauma. Although the same designation criteria are ap-
plied to hemophilia B, the correlation between plasma
levels and clinical outcome has not been rigorously
proven [4].
Before the advent of replacement therapy, the average
life span for a severe hemophilia patient was 13 years. A
monograph published in 1937 [5] examined the fate of
98 severe hemophilia patients; 83 died before age 16,
and only 6 survived to age 40. Further, 24 of the 98 died
from minor surgery or insignificant injuries, such as bit-
ing their tongue or cutting a finger. After the develop-
ment of specific purified or recombinant FIX and FVIII
molecules for replacement therapy, the average age of
survival of hemophilia patients increased to about
60 years.
The standard of care has, until recently, been to treat
patients for severe bleeding episodes as they occur (on
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demand). Recently, however, the World Federation of
Hemophilia recommends that on-demand treatment be
replaced by prophylaxis [6]. The goal is to prevent osteo-
arthritis caused by bleeding into joints.
Currently, clinical practice guidelines for prophylactic
hemophilia treatment requires 2–3 infusions per week.
However, several companies have developed new, “lon-
ger lasting” FIX molecules; these have been designed to
have a longer plasma half-life, and thus theoretically
allow patients to go 7–10 days between injections [7–9].
While the published half-life data on these “longer
lasting” molecules is impressive, the extravascular role of
FIX has not been considered. It is standard clinical prac-
tice to treat hemophilia as though the plasma concentra-
tion of FIX is the only significant criterion. However,
this ignores the significant evidence for the existence of
extravascular FIX and the role that it plays in coagula-
tion. The following observations provide evidence that
the naturally occurring extravascular stores of FIX are
physiologically important. First, FIX binds reversibly and
saturably to type IV collagen [10]. Second, a mouse ex-
pressing human FIX (FIXK5A, which has a specific activ-
ity in vitro of up to twofold greater than that of FIXWT,
but a reduced affinity for type IV collagen) has a bleed-
ing diathesis, even though its circulating level of FIXK5A
is about 20 % higher than normal [11]; the mouse ex-
hibits this bleeding diathesis although both the plasma
levels and specific activity are higher for the FIX in the
FIXK5A mouse. Third, we infused hemophilia B mice
with a FIX variant (FIXK5R) that binds more tightly to
type IV collagen than does FIXWT. The mice dosed with
FIXK5R clotted more efficiently mice infused with FIXWT;
this occurred despite the fact that circulating FIX levels
were unmeasurable 3 days post-infusion [12] . There is
also excellent evidence of an extravascular reservoir of
FIX in baboons. Stern et al. demonstrated quite clearly
that administering increasing amounts of bovine FIX
into the baboon rapidly displaced endogenous stores of
extravascular baboon FIX into the plasma [13]. In Fig. 1,
Stern et al. infused baboons with bovine FIX and then
followed the release of baboon FIX into the plasma. This
was possible due to a specific antibody for bovine FIX
that allows the measurement of baboon FIX with min-
imal cross-reactivity with bovine FIX. Clearly, in the ba-
boon experiments, at least 3 times more FIX is released,
presumably from an extravascular collagen IV compart-
ment, than is found in the baboons’ plasma.
Figure 2 shows that, at doses of 50, 100 and 150 IU/
kg, Alprolix and BeneFIX respond almost identically in
hemophilia B mice tested using a saphenous vein bleed-
ing model, and that maximum efficacy is achieved at a
dose of about 150 IU/kg. Figure 2 shows that, for opti-
mal long-term therapy, 150 IU/kg is best, at least in
mice. In Fig. 2, hemophilia B mice were infused with
BeneFIX at doses of 50, 100, 150, 200, 250, and 500 IU/
kg and Alprolix at doses of 50, 100, 150 and 250 IU/kg.
These data were tested using a saphenous vein bleeding
model and were, for each dose and molecule, observed
7 days post-infusion.
We utilized homologous recombination to replace de-
fective mouse FIX in our hemophilia B mice [14], creat-
ing the FIXK5A mouse, which has a reduced FIX affinity
for collagen IV [15]. This FIXK5A mouse has a mild
bleeding diathesis, although it has 120 % of the circulat-
ing FIXK5A of WT mice—even though the FIXK5R dis-
plays about a twofold increase in specific activity over
the FIXWT mouse in an APTT assay [16, 17]. Figure 3
shows the efficacy of FIXWT and FIXK5A in mice (data
Fig. 1 Comparison of the ability of different concentrations of bovine
factor IX to displace baboon factor IX from its extravascular pool.
Redrawn from Stern et al. Br J. Haemat. 66:227. (1987). Adult baboons
were infused with the indicated amounts of bovine FIX, and the amount
of baboon FIX in the plasma was measured over the first
15 min post-infusion
Fig. 2 Comparison of different doses of factor IX to effect hemostasis
seven days post-infusion in hemophilia B mice. From: Cooley et al. Blood.
128:286. (2016). Doses of 50, 100, 150, 250, and 500 IU/kg of either
Alprolix or Benefix were infused into hemophilia B mice. After 7 days, the
ability of the mice to maintain hemostasis was evaluated by the
saphenous vein bleeding model. At least 20 mice were used for
each dose
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taken using the saphenous vein model). Clearly there is
a bleeding diathesis associated with reduced FIX affinity
for collagen IV, even though the FIX plasma activity in
these mice is higher than in the wild-type mice.
What causes this cessation of bleeding when FIX is at
immeasurable levels in the plasma? Is it residual FIX cir-
culating FIX that is below the limits of detection but still
effective? Is it collagen IV-bound, extravascular FIX? We
examined this question recently in a paper published in
Blood [18]. First we performed a saphenous vein injury
on one side of the mouse and measured how many times
bleeding could be terminated. Any unmeasurable, re-
sidual circulating FIX should have been exhausted when
the first vein lost the ability to clot. We then injured the
contralateral vein and measured the number of times
that clotting from the injury ceases the bleeding. The
clotting efficacy for the contralateral vein was essentially
identical to that of the initial injury (Fig. 4). This appears
to mean that the local extravascular FIX, not the circu-
lating FIX, is critical for the cessation of bleeding—at
least in this model of coagulation efficacy.
Are FIX’s pharmacokinetics consistent with rates of
disappearance from plasma?
One question that is frequently asked is: what about the
on and off rates for proteins? Are they really consistent
with FIX binding to collagen IV? It is very difficult to
obtain this data, and the limited number of data points
make the results approximate. But when Stern’s data is
fitted to a simple differential equation that assumes that
the only thing going on in the first 10 min post-infusion
is binding to collagen IV, the resulting numbers are con-
sistent with the in-vitro measured KD values of around 5
nM (Fig. 5). For example, in Stern’s data, the rate of
displacement of baboon FIX into the plasma is around
0.003 per second, while the association rate constant is
about 3 × 105 per second per mole. These values are
typical on and off rates for proteins [19].
How much extravascular FIX is expected?
If we assume that FIX’s binding affinity for collagen IV is
5 nM and that the FIX plasma concentration is 90 nM,
then approximately 95 % of the total FIX will be bound
to available type IV collagen. This predicts that about
20-fold more extravascular FIX is present outside the
vasculature than is found in the circulation. This would
be true unless the collagen IV were limiting. While it is
Fig. 3 Comparison of the hemostatic ability of wild-type mice and
hemophilia B mice whose endogenous factor IX was exchanged for
FIXK5A. From: Cooley et al. Blood. 128:286. (2016). A mouse expressing
FIXK5A from its endogenous promoter was compared to a wild-type
mouse using the saphenous vein bleeding model. The activity level of
the FIXK5A in the plasma of this mouse was slightly higher than that of
the wild-type mouse. The mouse expressing FIXK5A nevertheless has a
bleeding diathesis
Fig. 4 An examination of the ability of FIX (BeneFIX) to effect
hemostasis 7 days post-infusion, after the ability of a first injury to effect
clotting has been exhausted. From: Cooley et al. Blood. 128:286. (2016).
Seven days post-infusion, the right saphenous vein was injured and
the number of times that re-clotting ensued was determined. After the
first injury was unable to continue clotting, the contralateral vein was
injured and hemostatic efficacy was again measured. Presumably, any
residual plasma FIX would have been used up during the first injury
had plasma FIX been required for clotting
Fig. 5 A fit of Stern’s data [Stern et al. Br J. Haemat. 66:227. (1987)]
to a simple set of differential equations describing equilibrium.
Stern’s data was digitized and fit to a simple differential equation
with the assumption that, during the first 10 min after infusion, only
equilibrium between FIX and type IV collagen occurs. The numbers
are at least consistent with in vitro measurements of the binding
constants between FIX and collagen IV
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difficult to estimate the total amount of collagen IV
in the body, it is likely that there is much more colla-
gen IV than would be saturated by our proposed op-
timal dosage of 150 IU/kg of FIX (if all of the infused
150 IU/kg FIX were retained in the plasma, the molar
concentration of FIX would be about 340 nM). Satur-
ation of the extravascular sites at concentrations of
FIX of around 300 to 400 nM agrees very well with
the values necessary to get kinetic constants with
pharmacokinetic data. The 300 to 400 nM number
also agrees with Stern’s data on the displacement of
baboon FIX by bovine FIX with theoretical plots.
How can we explain the lack of binding of FIX to much of
the available collagen IV?
Much of the body’s collagen IV is probably not normally
in contact with plasma-borne FIX. But the sinusoids,
which do not bind FIX, clearly are exposed to the circu-
lation. A possible explanation for this discrepancy is that
post-translational modification of collagen IV is required
to prevent binding of FIX to regions of collagen IV that
are readily accessible to blood. An example is provided
recently by a report that a specific prolyl hydroxylase is
required to prevent lethal platelet aggregation via the
platelet receptor GPVI [20]. A similar post-translational
modification could render the collagen IV lining the si-
nusoids incapable of binding with FIX.
Thrombosis at higher doses
The best evidence against a slight elevation of FIX caus-
ing a significant risk of thrombosis comes from a par-
ticular group of patients whose FIX—FIX Padua
(FIXR333L)—has a specific activity that is about eight
times greater than that of FIXWT [21]. Affected males
develop thromboses at around 16–20 years of age, but
the heterozygous mother, whose FIX activity is increased
to almost 4 times that of FIXWT, has had no problems
with thrombosis. The FIX Padua patients in the Simioni
study are chronically exposed to FIX that, while present
at normal doses, has an eightfold increase in specific ac-
tivity, which should be equivalent to the activity of 8
times the normal amount of circulating FIX. By contrast,
hemophilia B patients infused with 150 IU/kg of FIX
would be only transiently exposed to higher doses of cir-
culating FIX. For example, in our experiments that
injected different amounts of FIX into hemophilia B
mice, we found that at a dose of 150 IU/kg, the increased
level of plasma exposure lasts for less than 2 min. Even
at doses of 320 IU/kg, the plasma level of FIX decreases
to normal levels in mice by the 30-min mark. More im-
portantly, the studies that correlate circulating FIX activ-
ity to thrombosis risk do not consider the relatively large
extravascular reservoir of FIX. For example, a plasma
level of 5 mcg/mL would imply a total dose of FIX of at
least 22.5 mcg/mL—equivalent to a dose of about
180 IU/kg of FIX. So a dose of 150–200 IU/kg given to a
patient with no circulating levels of FIX antigen is very
nearly the same (or less) than the total amount present
in normal individuals. Clearly, not all the loss of FIX
from circulation is caused by clearance in the traditional
sense, because infused hemophilia B mice continue to
exhibit relatively good function—even 7 days post-
infusion, when no FIX has been detectible in the circula-
tion since day 3 post-infusion. In mice, Alprolix and
BeneFIX protect from bleeding for 7 days with essen-
tially identical efficacy.
Conclusions
The cumulative thrust of these studies sheds light on the
reports that, at the same plasma levels of activity, FVIII
mutations appear to be more severe than FIX mutations
expressing the same levels of FIX activity [22, 23]. This
difference may be explained by the role of extravascular
FIX in coagulation—a significant proportion of FIX is
extravascular, and this extravascular FIX remains active.
Presumably, FVIII does not have significant extravascu-
lar stores.
The assumption that plasma FIX concentrations are
the best marker of FIX supplementation efficacy is thus
not completely true. FIX is also found distributed
around the extra-vasculature throughout the body. The
sites that react with antibodies to FIX also react with
antibodies to type IV collagen (although not all of the
apparently readily available collagen IV in the body re-
acts with FIX antibodies).
Accumulating data suggest that the extravascular com-
partment approaches saturation at around 150 IU/kg;
therefore we suggest that, an appropriate dose of FIX
would be around 150 IU/kg. Longer time points should
also be tested in future experiments, since, at this dose,
there is still rather robust control at 7 days post-
infusion.
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